CA-POINT2WEB
31.7.2024 18:54:28 CEST | Business Wire | Press release
Point2Web, your ultimate marketing powerhouse in creative, advertising, and performance marketing, is thrilled to announce its appointment as the first Agency Sales Partner in Europe for NewsBreak, America's leading platform for local news and information, with over 40 million monthly active users.
Together, Point2Web and NewsBreak are poised to deliver exceptional advertising solutions that deeply engage local audiences. This partnership aims to drive significant growth and performance for Point2Web clients by combining the strengths of both companies to create something truly groundbreaking. The collaboration is expected to foster innovation, enhance service excellence, and achieve positive results for NewsBreak’s local users and their communities across America.
By utilizing NewsBreak's innovative technology and unrivaled local footprint, brands can revolutionize their local and targeted advertising and help direct resources where they are needed most. Point2Web's industry-leading expertise will further enable clients to amplify their advertising impact on an unprecedented scale. The collaboration will be particularly beneficial to advertisers in insurance, finance, travel, home improvement, e-commerce, and casual gaming, among others.
Partnership Highlights:
- Extended Reach: Point2Web clients will now have access to NewsBreak's 40 million users across the U.S., significantly enhancing the impact of their advertising campaigns. This access ensures advertisers can reach a vast yet highly engaged user base.
- Innovative Solutions: The partnership brings NewsBreak's use of new technology to Point2Web's clientele.
- Global Expertise, Local Impact: Point2Web's global presence and deep expertise in performance networks, combined with NewsBreak's robust local information platform, ensures a targeted and effective advertising strategy that will resonate with local communities. This synergy enables advertisers to craft messages that are both globally informed and locally relevant.
- Fostering Innovation and Achieving Success: Both Point2Web and NewsBreak share a strong commitment to innovation, excellence in service, and achieving positive results for their stakeholders. This partnership is a testament to their joint vision of pushing the boundaries of what is possible in digital advertising.
“Through our partnership with NewsBreak, we’re not just expanding the digital footprint of our clients; we’re providing them with the tools and platforms necessary to achieve unprecedented levels of engagement and success in their advertising campaigns,” said Valentine Kovalenko, COO at Point2Web. “This collaboration is a testament to our unwavering commitment to innovation and excellence in service. NewsBreak’s audience is highly engaged and of high quality, which ensures that our clients' ads reach a valuable and responsive demographic.”
“We are thrilled to partner with Point2Web, whose global expertise and innovative approach align perfectly with our mission to create a local media ecosystem where information is readily available and easily accessible," said Ryan Ludlow, General Manager of NewsBreak Advertising. "By leveraging our cutting-edge new technology and working with strategic partners like Point2Web, we remain dedicated to enhancing advertiser success and maintaining our focus on ad quality.”
For more information about this partnership and how it can benefit your advertising strategies, please visit our website.
About Point2Web
Point2Web is a global advertising agency that specializes in performance marketing and exceptional creative development. We unite media buying, creative development, and agency access to top-tier ad platforms to provide a powerful blend of services, expertise, and exclusive partnerships around the globe.
Our dedication to excellence and innovation is evident in every project we undertake. Our brand is anchored by our core values: reliability, mutual trust, top-tier service, steadfast commitment, and unending innovation. As we expand our horizons, Point2Web is committed to transparency, integrity, and achieving superior results for our clients.
We redefine the standard with our forward-thinking mindset and the latest in technology, setting new benchmarks in creativity. With a footprint in nine countries, advertisers and publishers worldwide can benefit from our unwavering commitment to driving their growth.
About NewsBreak
NewsBreak is the leading platform for local news and information in the United States, providing users with the local news and information they want and need in a digital form. By using cutting-edge technology that learns users’ preferences to curate tailored content for them, NewsBreak gathers community-focused news and information from over 10,000 sources in a timely, accessible, and easy-to-use way at no cost to users. NewsBreak is bridging the gap between new technology and traditional local media, offering an innovative digital solution that benefits everyone, from individual users and their communities to businesses across America.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240729481955/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom